Hospital Authority Toxicology Reference Laboratory, Princess Margaret Hospital, Kowloon, Hong Kong.
Clin Toxicol (Phila). 2021 May;59(5):426-432. doi: 10.1080/15563650.2020.1822529. Epub 2020 Sep 22.
This retrospective case-series study aims to provide an overview of the clinical, biochemical and analytical findings in patients who presented with toxicity related to the use of illegitimate slimming agents in Hong Kong from the perspective of a tertiary referral toxicology laboratory.
All clinical cases referred to the Hospital Authority Toxicology Reference Laboratory, Hong Kong with clinical suspicion of illegitimate slimming agent-related toxicity between January 2008 and December 2017 were reviewed retrospectively. The use of illegitimate slimming agents included the use of (1) deregistered slimming agents, (2) drug analogues that were not registered drugs, (3) registered drugs not approved for the indication of weight reduction (whether prescribed by a doctor or not), and (4) prescription-only slimming agents without a doctor's prescription. Patients taking registered weight-reducing drugs prescribed by a doctor were excluded. Patient demographics, clinical features, relevant laboratory investigations, and toxicological findings were analyzed.
From 2008 to 2017, a total of 346 patients were analytically confirmed by our laboratory to have clinical toxicity related to the use of illegitimate slimming agents. The median age of the patients was 27 years and 92.5% of the patients were female. The most common clinical presentations included psychiatric features, sympathomimetic toxicity, hypokalemia, and abnormal thyroid function tests. Fatal or severe clinical toxicity was observed in 10% of the cases. The major classes of drugs detected on our analytical platforms were stimulants (e.g., sibutramine), laxatives (e.g., anthraquinones), diuretics (e.g., hydrochlorothiazide), and thyroid hormones (e.g., animal thyroid tissue). These illegitimate slimming agents were obtained from various sources including the Internet, over-the-counter in community pharmacy, or unspecified local sources.
The use of slimming agents is common worldwide; apart from taking registered slimming agents prescribed by registered practitioners, many users obtain slimming agents from various illegitimate sources. The unregulated use of these drugs can be associated with significant clinical toxicity. This study provides a current landscape of illegitimate slimming agent toxicity in Hong Kong to frontline clinicians and other toxicology professionals. Collaboration between clinicians, laboratories, and government authorities would be imperative to prevent further health adversities related to the misuse of these agents.
本回顾性病例系列研究旨在从三级转介毒理学实验室的角度,提供香港因使用非法减肥药而导致毒性的患者的临床、生化和分析结果概述。
回顾性分析 2008 年 1 月至 2017 年 12 月期间因疑似与非法减肥药相关的毒性而转至香港医管局毒理学参考实验室的所有临床病例。使用非法减肥药包括:(1)已注销减肥药;(2)未注册药物的药物类似物;(3)未批准用于减肥适应症的注册药物(无论是否由医生开具处方);(4)无医生处方的处方减肥药。排除服用医生开具的注册减肥药的患者。分析患者的人口统计学特征、临床特征、相关实验室检查和毒理学发现。
2008 年至 2017 年,我院实验室共分析确诊 346 例与使用非法减肥药相关的临床毒性患者。患者的中位年龄为 27 岁,92.5%的患者为女性。最常见的临床表现包括精神症状、拟交感神经毒性、低钾血症和甲状腺功能异常。10%的病例观察到致命或严重的临床毒性。在我们的分析平台上检测到的主要药物类别包括兴奋剂(如西布曲明)、泻药(如蒽醌)、利尿剂(如氢氯噻嗪)和甲状腺激素(如动物甲状腺组织)。这些非法减肥药来自互联网、社区药房的非处方购买或未指明的本地来源。
减肥药的使用在全球范围内很常见;除了服用注册医生开具的注册减肥药外,许多使用者还从各种非法来源获得减肥药。这些药物的不受监管使用可能与严重的临床毒性有关。本研究提供了香港非法减肥药毒性的最新情况,供一线临床医生和其他毒理学专业人员参考。临床医生、实验室和政府当局之间的合作对于防止与这些药物滥用相关的进一步健康危害至关重要。